[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635808":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":27,"locations":35,"responsibleParty":54,"collaborators":10,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Participants with obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten",[13],"Drug: Mavacamten",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Physicians treating patients diagnosed with obstructive hypertrophic cardiomyopathy (oHCM)",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Mavacamten","According to the product label",[9,15],[25],{"name":5,"affiliation":5,"role":26},"STUDY_DIRECTOR",[28,33],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":34,"role":30,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[36],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Adelphi Real World","RECRUITING","Bollington","Macclesfield","SK10 5JB","United Kingdom","UK",{"type":45,"coordinates":46},"Point",[47,48],-2.10963,53.29446,{"lat":48,"lon":47},[51],{"name":52,"role":30,"phone":53,"phoneExt":10,"email":10},"USA Generic Country, Site 0001","0000000000",{"type":55,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100635808",false,"NCT07557498","Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US","Mavacamten Real-World OutcomeS and the Associated PAtient and Physician ExpeRienCe With Hypertrophic CardioMyopathy in the United States (US) Community","SPARC-HCM","Inclusion Criteria:\n\nPhase I: retrospective chart review\n\nFor inclusion in the study, participants must meet ALL of the following criteria:\n\n* Are an adult aged 18 or over at baseline\n* Have a confirmed diagnosis of obstructive hypertrophic cardiomyopathy (HCM)\n* Have been prescribed mavacamten for obstructive HCM at one of the study sites between 28th April 2022 and 31st December 2024\n* Have not ever been enrolled in any interventional clinical trial involving any cardiac myosin inhibitor (enrollment in observational studies is permitted)\n* Are not enrolled in any interventional clinical trial at study baseline\n\nPhase II: patient survey • Participants must meet all inclusion criteria of Phase I: retrospective chart review and be able to read and understand English and have access to computer or smartphone to complete the survey\n\nExclusion Criteria:\n\n• None with the proviso that all inclusion criteria are met.","ALL","18 Years",{"count":66,"type":67},362,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to understand the real-world clinical outcomes and treatment patterns of adults with obstructive hypertrophic cardiomyopathy (HCM) treated with mavacamten, and to understand patient and physician experiences with mavacamten treatment, in the US community-based practice",[71],"Obstructive Hypertrophic Cardiomyopathy (oHCM)",[73],"Obstructive Hypertrophic cardiomyopathy (oHCM)","2026-04-23",{"date":76,"type":77},"2026-04-29","ACTUAL",{"date":79,"type":77},"2026-01-15",{"date":81,"type":67},"2027-06-17",{"name":5,"class":6},1]